rethinkPeptides Search
Menu
Study breakdown

Substance P Protects Corneal Cells from Dry Eye-Related Damage by Activating Survival Pathways

evidence
The takeaway

Substance P prevented corneal epithelial cell death caused by hyperosmotic stress (a key mechanism in dry eye) by activating the Akt survival pathway and neutralizing harmful reactive oxygen species through the NK-1 receptor.

Multi-pathway corneal protection

Substance P simultaneously activated cell survival signaling (Akt), restored mitochondrial function, and neutralized oxidative stress — addressing multiple mechanisms of corneal cell death in dry eye.

What the researchers found

Substance P protected mouse corneal epithelial cells from hyperosmotic stress-induced apoptosis through multiple mechanisms working through the NK-1 receptor:

- Restored phosphorylated Akt levels (cell survival signaling)

- Recovered mitochondrial membrane potential

- Normalized intracellular calcium levels

- Scavenged reactive oxygen species (ROS)

- Restored glutathione levels (antioxidant defense)

Blocking the NK-1 receptor with an antagonist impaired both Akt activation and ROS scavenging, confirming that substance P's protective effects are mediated specifically through this receptor. Akt inhibition or glutathione depletion partially suppressed the anti-apoptotic capacity, demonstrating both pathways contribute to protection.

Why it matters

Dry eye disease affects hundreds of millions of people worldwide and current treatments primarily address symptoms rather than the underlying cell damage. This study reveals that substance P — already present in the cornea's nerve supply — can protect corneal cells from the specific type of damage that drives dry eye progression. This supports developing substance P-based eye drops as a disease-modifying treatment rather than just symptom relief.

How the study worked

Mouse corneal epithelial cells were cultured and exposed to hyperosmotic stress (high glucose). Cells were treated with substance P in the presence or absence of specific inhibitors: an Akt inhibitor, a glutathione-depleting agent, and an NK-1 receptor antagonist. Endpoints included apoptosis rates, Akt phosphorylation, mitochondrial membrane potential, calcium levels, ROS levels, and glutathione concentrations.

What this study cannot tell us

This is an in vitro study using mouse corneal epithelial cell lines, which may not fully replicate human corneal biology or the complex tear film environment. Hyperosmotic stress was induced with high glucose, which may have metabolic effects beyond osmolarity. The study did not test whether substance P can be effectively delivered as eye drops. In vivo validation in animal dry eye models was not performed. The dose-response relationship for substance P protection was not characterized.

How to read the evidence

This is a well-designed in vitro mechanistic study that clearly delineates the protective pathways of substance P in corneal cells. However, all findings are from cell culture experiments without in vivo validation, limiting clinical applicability.

When this study was published

Published in 2016, this study established key mechanistic insights about substance P's protective role in the cornea. Subsequent research has continued to explore neuropeptide-based approaches to dry eye treatment.

The bigger picture

Substance P is a neuropeptide with well-known roles in pain and inflammation, but in the cornea it appears to serve a protective function. This study adds to growing evidence that neuropeptides from corneal nerves are essential for maintaining ocular surface health. The loss of corneal innervation (neurotrophic keratopathy) leads to severe dry eye and corneal damage, partly because protective neuropeptides like substance P are no longer delivered to the tissue.

Questions still open

  • Can substance P eye drops effectively treat dry eye disease in human patients?
  • Does reduced corneal nerve-derived substance P contribute to dry eye progression in neurotrophic keratopathy?
  • Would combining substance P with existing dry eye treatments provide additive or synergistic benefits?

Common questions

How does substance P protect the cornea in dry eye conditions?
When tears become too concentrated (hyperosmotic), they stress and kill corneal cells. Substance P prevents this cell death by activating survival signaling, restoring energy-producing mitochondrial function, and neutralizing damaging reactive oxygen species — all through the NK-1 receptor on corneal cells.
Could substance P become a treatment for dry eye disease?
This study provides a strong scientific foundation for that possibility. Substance P naturally protects corneal cells from the type of damage that occurs in dry eye. While substance P eye drops haven't been clinically developed yet, the detailed understanding of how it works supports future therapeutic development.

Read the original research

Substance P Inhibits Hyperosmotic Stress-Induced Apoptosis in Corneal Epithelial Cells through the Mechanism of Akt Activation and Reactive Oxygen Species Scavenging via the Neurokinin-1 Receptor.

PloS one, 11(2), e0149865

Citation

Yang, Lingling; Sui, Wenjie; Li, Yunqiu; Qi, Xia; Wang, Yao; Zhou, Qingjun; Gao, Hua. (2016). Substance P Inhibits Hyperosmotic Stress-Induced Apoptosis in Corneal Epithelial Cells through the Mechanism of Akt Activation and Reactive Oxygen Species Scavenging via the Neurokinin-1 Receptor.. PloS one, 11(2), e0149865. https://doi.org/10.1371/journal.pone.0149865